HomeCommentary

Commentary

There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
(Aug.3.2018)

By Yoshinori Sagehashi

The Japanese biosimilar market is expected to triple from 16 billion yen in FY2015 to 46 billion yen in FY2021, with the market of target biologics also expanding from 120 billion yen to 700 billion yen, according to an estimate compiled in 2016 by Pfizer, IQVIA (then QuintilesIMS), and Prof. Hisashi Yamanaka of Tokyo Women’s Medical University. Given their still-sluggish uptake in Japan, there is still plenty of room for growth in the biosimilar arena, but companies appear wary ...

(LOG IN FOR FULL STORY)